Ana Garcia
Family Medicine · Miami, FLNPI 1093161275
Payments from drug & device makers
Across 804 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- AbbVie$1K
- Amgen$1K
- Sanofi-aventis U.S. LLC$1K
- Lilly USA, LLC$1K
- plus $8K from 47 others
What the payments were for
- Food & beverage$15,685100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,685 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $148,272 |
| JardianceEmpagliflozin | 40 | $65,167 |
| FarxigaDapagliflozin Propanediol | 32 | $46,174 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $39,593 |
| EntrestoSacubitril/Valsartan | 18 | $30,694 |
| EliquisApixaban | 25 | $28,782 |
| VascepaIcosapent Ethyl | 38 | $24,229 |
| SynjardyEmpagliflozin/Metformin Hcl | 24 | $17,760 |
| Omega-3 Acid Ethyl Esters | 86 | $8,972 |
| Rosuvastatin Calcium | 154 | $2,329 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,182 |
| SynthroidLevothyroxine Sodium | 15 | $1,992 |
| Diclofenac Sodium | 79 | $1,811 |
| Levothyroxine Sodium | 112 | $1,595 |
| Tadalafil | 20 | $1,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,611 | $148,272111 claims |
| Boehringer IngelheimJardiance, Synjardy | $370 | $82,92664 claims |
| AstraZenecaFarxiga | $1,581 | $46,17432 claims |
| GSKTrelegy Ellipta | $732 | $39,59337 claims |
| NovartisEntresto | $950 | $30,69418 claims |
| PfizerEliquis | $299 | $28,78225 claims |
| AbbVieSynthroid | $1,460 | $1,99215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Keila HooverMiami$33.7M
- Jorge CasoMiami$22.6M
- David WyattMiami$13.7M
- Jose CardenasMiami$13.2M
- Lazaro GarciaMiami$10.3M
- Ibrahim Menendez PerezMiami$8.9M
- Aniel Navarro MarinMiami$7.3M
- Gilberto SecoMiami$6.8M
- Ramon LeonMiami$6.3M
- Eddy CapoteMiami$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.